Correct but no point having the safest drug in the world if it has no efficacy - safety is pretty much a given - no dropouts and at AGM , numerous FDA meetings re safety had nothing to report. Secondary endpoints are the key. Going from the medical journal of FB there are compelling stories - but unfortunately at the moment they are just that. In saying that with an A-grade management team , strong trial design and numerous measurable secondary endpoints I'm quietly confident. We hav a lot of the right boxes ticked vs the other failed biotechs. Can't really compare them and there failures.
Not long now either way - if positive the flood of $$ into this will send the SP into the stratosphere
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)